StockData
Charles River Laboratories International, Inc. logo

Charles River Laboratories International, Inc. (CRL) stock

CRLNYSEServices-Commercial Physical & Biological ResearchFiscal year ends December 27
Financials through Q2 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30215% above fair value
$333.25+1.09 (+0.33%)

Close on Nov 18, 2026Market cap $15.91BP/E –Yield –

Charles River Laboratories International revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Charles River Laboratories International's revenue for the twelve months ending Jun 27, 2026 was $4.00B, down 0.7% year over year. For fiscal 2025 it was $4.02B, down 0.9% from the year before. Over ten years it grew 11.4% a year on average. The highest annual figure on record is $4.13B in fiscal 2023.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 27, 2025$4.02B-0.9%
FY2024Dec 28, 2024$4.05B-1.9%
FY2023Dec 30, 2023$4.13B+3.9%
FY2022Dec 31, 2022$3.98B+12.3%
FY2021Dec 25, 2021$3.54B+21.1%
FY2020Dec 26, 2020$2.92B+11.5%
FY2019Dec 28, 2019$2.62B+15.7%
FY2018Dec 29, 2018$2.27B+22.0%
FY2017Dec 30, 2017$1.86B+10.5%
FY2016Dec 31, 2016$1.68B+23.3%
FY2015Dec 26, 2015$1.36B+5.1%
FY2014Dec 27, 2014$1.30B+11.3%
FY2013Dec 28, 2013$1.17B+3.2%
FY2012Dec 29, 2012$1.13B-1.1%
FY2011Dec 31, 2011$1.14B+0.8%
FY2010Dec 25, 2010$1.13B-3.3%
FY2009Dec 26, 2009$1.17B-9.5%
FY2008Dec 27, 2008$1.30B–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 27, 2026$1.00B-2.7%
Q1 FY2026Mar 28, 2026$995.83M+1.2%
Q4 FY2025Dec 27, 2025$994.23M-0.8%
Q3 FY2025Sep 27, 2025$1.00B-0.5%
Q2 FY2025Jun 28, 2025$1.03B+0.6%
Q1 FY2025Mar 29, 2025$984.17M-2.7%
Q4 FY2024Dec 28, 2024$1.00B-1.1%
Q3 FY2024Sep 28, 2024$1.01B-1.6%
Q2 FY2024Jun 29, 2024$1.03B-3.2%
Q1 FY2024Mar 30, 2024$1.01B-1.7%
Q4 FY2023Dec 30, 2023$1.01B-7.9%
Q3 FY2023Sep 30, 2023$1.03B+3.8%
Q2 FY2023Jul 1, 2023$1.06B+8.9%
Q1 FY2023Apr 1, 2023$1.03B+12.6%
Q4 FY2022Dec 31, 2022$1.10B+21.5%
Q3 FY2022Sep 24, 2022$989.16M+10.4%
Q2 FY2022Jun 25, 2022$973.13M+6.4%
Q1 FY2022Mar 26, 2022$913.93M+10.8%
Q4 FY2021Dec 25, 2021$905.05M+14.4%
Q3 FY2021Sep 25, 2021$895.94M+20.5%
Q2 FY2021Jun 26, 2021$914.61M+34.0%
Q1 FY2021Mar 27, 2021$824.57M+16.6%
Q4 FY2020Dec 26, 2020$790.99M+14.4%
Q3 FY2020Sep 26, 2020$743.30M+11.3%
Q2 FY2020Jun 27, 2020$682.58M+3.8%
Q1 FY2020Mar 28, 2020$707.06M+17.0%
Q4 FY2019Dec 28, 2019$691.14M+14.9%
Q3 FY2019Sep 28, 2019$667.95M+14.1%
Q2 FY2019Jun 29, 2019$657.57M+12.3%
Q1 FY2019Mar 30, 2019$604.57M+22.4%
Q4 FY2018Dec 29, 2018$601.53M+25.7%
Q3 FY2018Sep 29, 2018$585.30M+26.1%
Q2 FY2018Jun 30, 2018$585.30M+24.8%
Q1 FY2018Mar 31, 2018$493.97M+10.8%
Q4 FY2017Dec 30, 2017$478.48M+2.5%
Q3 FY2017Sep 30, 2017$464.23M+9.0%
Q2 FY2017Jul 1, 2017$469.13M–
Q1 FY2017Apr 1, 2017$445.76M–
Q4 FY2016Dec 31, 2016$466.79M–
Q3 FY2016Sep 24, 2016$425.72M–

More Charles River Laboratories International figures

See a number that looks wrong?